HMG CoA reductase inhibitor [statin] therapy should be considered for older patients

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1237, 2000-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A switch from current HMG CoA reductase inhibitor [statin] therapy to either cerivastatin 0.4 or 0.8 mg/day or simvastatin 80 mg/day

Inpharma, Vol. 1, Iss. 1307, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

HMG CoA reductase inhibitor therapy underused after CAGB

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 364, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The HMG CoA reductase inhibitor [statin] atorvastatin [`Lipitor'; Pfizer], has garnered a Q3 sales increase

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 339, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitor (Statin) Therapy and Coronary Atherosclerosis in Japanese Subjects: Role of High-Density Lipoprotein Cholesterol

By Tani Shigemasa Nagao Ken Hirayama Atsushi

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. : 411-417

Adis International

Access to resources Recommend Favorite

Cerivastatin: the low-dose HMG-COA reductase inhibitor

By Tikkanen M.J.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 1, 2000-01 ,pp. : 161-166

Informa Healthcare

Access to resources Recommend Favorite